D. Western Therapeutics Institute, Inc. (TSE: 4576)
Health Care · Biotechnology · JP
¥69.00
-1.43% today · -34.3% 1Y
D. Western Therapeutics Institute, Inc. (TSE: 4576) operates in the Biotechnology industry within the Health Care sector. The company is valued at $25.15M and employs 19 people.
Over the last twelve months the share price has lost 34.3%, trading between 66.00 and 111.00.
Tweenvest scores D. Western Therapeutics Institute, Inc. across four factors: quality 52/100, value 31/100, growth 0/100. Its strongest factor is quality.
4576 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $25.15M
- Revenue (TTM)
- $1.52M
- P/E
- —
- EPS
- -11.97
- Dividend yield
- —
- Beta (5Y)
- 0.04
- 52-week high
- ¥111.00
- 52-week low
- ¥66.00
- Avg volume (3M)
- —
- Shares outstanding
- 57.55M
- Employees
- 19
- Next earnings
- —
About D. Western Therapeutics Institute, Inc.
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed for glaucoma and ocular hypertension, as well as DW-1001, another medication for eye conditions. It also provides DWR-2206, a regenerative cell-based product targeting bullous keratopathy, and DW-1002, an ophthalmic surgical aid used for staining membranes like ILM, ALC, ERM, and PVR during cataract operations. In its development pipeline, the company is advancing DW-5LBT, a lidocaine patch designed to alleviate neuropathic pain post-shingles. Additionally, K-321 is progressing through Phase III clinical trials for Fuch endothelial corneal dystrophy, and H-1337, a multi-kinase inhibitor, has commenced Phase IIb trials for glaucoma and ocular hypertension treatment. The firm was established in 1999 and operates from its headquarters in Nagoya, Japan.
- ISIN
- JP3548740004
- Founded
- 1999
- Listed since
- Oct 23, 2009
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Noile-Immune Biotech Inc.TSE: 4893 | $25.84M | ¥94.00 | -7.84% |
| Seoulin Bioscience Co.,Ltd.KOSDAQ: A038070 | $25.81M | ₩3,810.00 | -6.39% |
| Genesystem Co., Ltd.KOSDAQ: A363250 | $25.76M | ₩4,145.00 | +1.97% |
| Kainos Medicine, Inc.KOSDAQ: A284620 | $25.58M | ₩— | — |
| Immutep LimitedASX: IMM | $24.85M | AU$0.02 | +4.35% |
| Genvor IncorporatedOTCPK: GNVR | $24.85M | $0.68 | -24.17% |
| Thiogenesis Therapeutics, Corp.TSXV: TTI | $24.74M | CA$0.50 | -5.66% |
| Seres Therapeutics, Inc.NasdaqGS: MCRB | $24.71M | $2.46 | -9.23% |
Figures last refreshed Oct 18, 2026.